The frog natural product temporin-SHa (FLSGIVGMLGKLF amide ) is a potent antimicrobial peptide, as is the analog [S3K]SHa. By solid-phase synthesis, we prepared temporin-SHa and several temporin-SHa analogs with one or more D-alanine residues incorporated. The natural product and the analog [G10a]SHa were found to be cytotoxic in mammalian cell lines and induce cell death. To achieve selectivity, we conjugated the analog [G10a] SHa with a breast cancer targeting peptide (BCTP). The resulting peptide temporin [G10a]SHa-BCTP conjugate was selectively active against the MCF-7 breast cancer cell line with no cytotoxicity in NIH-3T3 fibroblasts. Unlike the natural product or [G10a]SHa, the conjugated peptide induced apoptosis, downregulating the expression of Bcl-2 and survivin and upregulating Bax and caspase-3.
Introduction
Cancer is a condition that refers to abnormal cell growth with the potential to invade other parts of the body, and is one of the main causes of mortality worldwide. Conventional treatments include radiation or chemotherapy which often lack selectivity against cancer cells. The deleterious side effects on healthy cells and tissues cause toxicity towards vital organs and severe inflammatory responses due to necrosis [1] [2] [3] [4] . To improve the selectivity of therapeutic agents, one strategy involves conjugation of the cytotoxic drug with targeting ligands such as antibodies or tumor targeting peptides that recognize specific receptors on particular types of cancer cells [5] [6] [7] [8] [9] [10] [11] [12] . Recently, a decapeptide sequence WXEAAYQXFL, with varied residues at X positions, was discovered to promote specific binding to breast cancer cell lines [10] [11] [12] . One of these breast cancer targeting peptides (BCTP), with D-norleucine and D-arginine residues in positions 2 and 8 respectively, was modified (r8k and C-terminal carboxyamidation) and then conjugated with the cytotoxic anticancer drug doxorubicin. The resulting conjugate exhibited selectivity for breast cancer cell lines compared to the parent drug [11] .
We were interested in applying the cancer targeting concept to antimicrobial peptides (AMPs). Although AMPs are primarily known for their antimicrobial properties, some examples and their derivatives are reported as potent antitumor agents with low toxicity such as temporin1CEa, ascaphin-8, alyteserin-2 and magainin-2 [13] [14] [15] [16] [17] . These AMPs bind to the plasma membrane and cause cell death by either necrosis or apoptosis [18] [19] [20] [21] . As a proof of concept, we started with the antimicrobial peptide temporin-SHa (FLSGIVGMLGKLF amide ). TemporinSHa was isolated from the skin of the Sahara frog Pelophylax saharicus and reported as an antimicrobial agent active against bacteria, yeasts and fungi [22, 23] . Temporin-SHa, the analogs temporin-[S3K]SHa and the L-alanine substituted temporin-[A2,6,9]SHa were not cytotoxic against mammalian cell lines such as THP-1 monocytes (IC 50 > 60 μM) and HepG2 cells (IC 50 > 600 μM) [23] . We synthesized various D-Ala substituted analogs of temporin-SHa and screened them against several cancer cell lines as well as 3T3 cells to identify analogs with anticancer activity. We then planned to conjugate the breast cancer targeting peptide (BCTP) [10] [11] [12] to the most potent analog to achieve selective 1 H and 13 C NMR spectra were recorded on Bruker NMR spectrometers (Bruker, Switzerland), operating at 600 MHz and 125 MHz, respectively. HRFAB-MS was recorded on JEOL JMS HX 110 mass spectrometers (Japan). All peptides were purified by using LC-908 W recycling preparative HPLC (Japan Analytical Industry) by using a Jaigel ODS-MAT 80 (C18) column. The purity of peptides was established by Ultra-Performance Liquid Chromatography (UPLC) (Agilent 1260 Infinity Diode Array, C-4 reversed-phase analytical column, 5 μm, 150 x 4.6 mm).
Peptide synthesis
Solid-phase synthesis was performed manually by using a step-wise Fmoc peptide synthesis protocol. Rink amide MBHA resin (0.51 mmol/ g, Novabiochem) soaked in DCM, was first treated with 20% 4-methylpiperidine to remove the Fmoc protecting group from Rink linker. Fmoc-protected phenylalanine (3 equiv), Oxyma pure (0.65 g, 3 equiv), and DIC (0.71 mL, 3 equiv) in 10 mL of DMF were added in the resin, and the suspension shaken overnight. Fmoc-phenylalanine loaded resin was then deprotected by 20% 4-methylpiperidine in DMF. The resin was then treated with the next Fmoc amino acid (3 equiv.) in DMF, Oxyma pure (3 equiv.) and DIC (3 equiv.). The reaction mixture was agitated for 2 h. Completion of reaction was checked by a ninhydrin colorimetric test. Through repeated couplings, the synthesis of all peptide sequences and [G10a]SHa-BCTP conjugate (Scheme S1) was completed with removal of the Fmoc group on the last residue. The peptides were then cleaved from the resin with 95% TFA, cocktail (94% TFA, 1% triisopropylsilane, 2.5% ethanedithiol, 2.5% water) for 2 h at room temperature. The crude peptide was precipitated with diethyl ether and recovered from centrifugation and then lyophilized. Further purification of peptides was carried out by RP-HPLC using acetonitrile / water (60:40) in 0.1% TFA at a flow rate of 4 mL / min.
Mass spectrometric analysis of peptides
Matrix-assisted laser desorption/ionization (MALDI) analysis was performed on an Ultraflex III TOF/TOF (Bruker Daltonics, Bremen, Germany) mass spectrometer. All peptides, dissolved in H 2 O/ ACN (40:60), 0.1% TFA, were mixed with 0.5 μL of the matrix (HCCA) solution (saturated solution in 0.1% TFA/CH 3 CN, 2:1), and deposited on a MALDI plate. Spectra were recorded as described earlier [24] . ESI-QTOF-MS spectra were recorded on a Q-STAR XL mass spectrometer (Applied Biosystems). Each peptide dissolved in 0.1% TFA/H 2 O/ ACN 40:60 was infused directly into the mass spectrometer at a flow rate of 3 μL/min to acquire full scan and product ion mass spectra. The electrospray voltage at the spraying needle was optimized at 5500 V. ) were purchased from ATCC. MCF-7 cells were used because these cells retain many ideal characteristics particular of differentiated mammary epithelium. NCI-H460 cell line is derived from non-small cell lung carcinoma [25] . NIH-3T3 cells are mouse fibroblast cells suitable for transfection studies and can be used as a non-cancerous model for cytotoxicity studies [26] . DoHH2 cells were 1 st isolated from pleural fluid of non-Hodgkin's lymphoma patient, act as representative of B-cell line (DoHH2) [27] . DoHH2 cells were kindly provided by Professor Daniel Hoessli from University of Geneva, Switzerland. HeLa cells were kindly donated by Dr. Anwar Siddiqui from Aga khan University Karachi, Pakistan. RPMI-1640 medium, FBS, and mouse anti-human-Bcl-2 primary antibody and mouse anti-human beta-actin primary antibody were purchased from The cytotoxic as well as antiproliferative effect of peptides was determined using MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] colorimetric assay. Briefly MCF-7, NIH-3T3, HeLa, and NCI-H460 cells were cultured, and after confluency, cells were used to test the cytotoxicity. MTT, a tetrazolium salt, was used to check the cytotoxicity of cultured cells [28] . MTT became reduced when exposed to oxidoreductase in viable cells, and transformed into purple formazan crystals. Briefly 6000 of MCF-7 cells per well and 4000 cells of NIH-3T3, HeLa and NCI-H460 cells per well were seeded in 96-wells plate and incubated at 37°C in 5% CO 2 for 24 h. MCF-7 cells were then treated with different doses of peptide [G10a]SHa (12.5, 25 and 50 μM) and [G10a]SHa-BCTP (25, 50 and 100 μM) and re-incubated in 5% CO 2 at 37°C for 48 h. The other cell lines were tested with different doses (1, 10 and 100 μM). Untreated control cells were treated with complete medium, while vehicle control cells with medium containing 0.5% DMSO. Doxorubicin, cycloheximide, and cisplatin were used as standard drugs for MCF-7, NIH-3T3 and NCI-H460, respectively. After 
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48 h, media containing compounds were removed and 200 μl medium containing (0.5 mg/ml) MTT was added to each well and re-incubated for 4 h at 37°C in 5% CO 2 . After 4 h, MTT containing media were removed and formazan crystals were solubilised in pure DMSO and absorbance was measured using photometer (Thermofisher, USA) at 550 nm wavelength. Experiment was performed three times and all doses were repeated in triplicate and the calculations were done using formula for percent inhibition. 
Alamar blue assay
The viability of DoHH2 cells was determined by Alamar blue assay. Briefly cells were grown in RPMI media supplemented with 10% FBS and 1% penicillin/ streptomycin. Upon reaching confluence 20,000 cells per well were incubated with different concentrations (1, 10, and 100 μM) of compounds for 24 h. A one-tenth volume of Alamar blue was then added, and the incubation continued for 4 h. Absorbance was read in spectrophotometer at wavelengths of 570 nm and 600 nm [29] . The concentration of DMSO used was 0.5% as it was the amount used to dissolve the highest dose of [G10a]SHa-BCTP conjugate (100 μM). One-way ANOVA reveals significant difference i.e., *p < 0.05, **p < 0.01 and ***p < 0.001 in comparison with control cells. (Fig. 3B) . Total 95% cells were gated and 10,000 cells were counted for each case. Positive control cells used in experiment were provided in the by the manufacturer (Kit number APT110, Millipore-Merck).
RNA isolation and complementary DNA synthesis
The MCF-7 cells were seeded (1 × 10 6 cells/well) in 6-well plate, and kept in 5% CO 2 at 37°C for overnight incubation. Next day, cells were treated with medium containing 0, 25, 50, and 100 μM dose of [G10a]SHa-BCTP conjugate for 24 h. Total RNA was isolated using TRIzol reagent by following the manufacturer's instructions. The isolated RNA was quantified and 260/280 ratios were calculated for RNA purity using NANOdrop ® . Agarose (1.2%) gel electrophoresis was run at 70 V for 45 min to determine the integrity of RNA isolated. RNA samples (1000 ng) with good integrity were used to synthesize cDNA using RevertAid ® first strand kit (ThermoScientific, USA).
Gene expression analysis
Real time gene expression analysis before and after treatment with [G10a]SHa-BCTP conjugate was performed on Stratagene Mx3000p (Agilent Technologies, USA) using Maxima SYBR green (Fermentas, USA). Each reaction consisted of gene specific primers (1 + 1 μl), cDNA template (2 μl), nuclease free water (6 μl) and 2X SYBR master mix (10 μl). Table 1 shows the primer sequences used in this study. Bcl-2 and survivin were chosen as anti-apoptotic genes in this analysis, and Bax and caspase-3 as pro-apoptotic genes. For the normalization of data, GAPDH was used as a reference gene. All the primers were designed to have the melting temperature between 55-60°C. Thermalcycling conditions were set as 95°C for 10 min (pre- 
Statistical analysis
The data were statistically analyzed using SPSS and Microsoft Excel. Mean and standard deviation were calculated from three replicates for MTT assay, real time PCR and ImageJ readings as representatives of Cells were then fixed, incubated with Bcl-2 primary/secondary antibodies and images were taken using fluorescence microscope (Nikon 90i microscope). Image J software was used to quantify the intensity of fluorescence light produced by images (Fig. E) . data. One-way ANOVA with Tukey's test was utilized to determine pvalues for the significance of data.
Results and discussion
Synthesis
Temporin-SHa (FLSGIVGMLGKLF amide ) and its analog [S3K]SHa are reported as potent antimicrobial peptides, while L-alanine-substituted analogs of SHa lack antibacterial and antiparasitic activities. A study regarding the antiparasitic activity of temporin-SHa revealed apoptotic cell death in Leishmania infantum [23] . To date, no anticancer activity of temporin-SHa or any of its analogs is reported.
Partial or entire D-amino acid substitution is reported as a useful approach to develop better therapeutic activities, to increase the resistance to proteolysis and to overcome many hurdles faced by host defense peptides [30, 31] . In the current study, the stereochemically more flexible achiral glycine residues at positions 4, 7 and/or 10 of temporin-SHa, were substituted with D-Ala residues to obtain several analogs (Table 2) through Fmoc solid-phase synthesis [31, 32] . The identity was assessed by matrix-assisted laser desorption/ ionization-time of flight (MALDI-TOF) mass spectrometry, HR-MALDI-TOF-MS, MALDI/MS/MS and NMR studies (Fig. S1-S16 , Table S1-S9).
[G10a]SHa-BCTP showed affinity and selectivity for MCF-7 cells
Many antimicrobial peptides were reported to possess anticancer activities. However, the antimicrobial peptide temporin-SHa was reported as non-cytotoxic against the HepG2 cell line [23] . We decided to perform anticancer screening of temporin-SHa and its analogs (Table 2) against different cancer cell lines as well as NIH-3T3 murine fibroblast cell line (Table 3) . Interestingly, the natural product temporin-SHa was found active against MCF-7, HeLa, and NCI-H460 cell lines with no cytotoxicity against DoHH2 cell line. The analog [G10a]SHa containing D-alanine in place of glycine at position 10 was found to be the most cytotoxic against MCF-7, HeLa and NCI-H460 cells among the peptides synthesized. Since it was cytotoxic to normal NIH-3T3 murine fibroblast cell line, we decided to improve selectivity by conjugating this peptide with the breast cancer targeting peptide (BCTP) ligand (WLEAAYQKFL) (Scheme S1), which afforded [G10a]SHa-BCTP conjugate (Fig. 1) .
The [G10a]SHa-BCTP conjugate was fully characterized by mass spectrometry (Table 2 ) and NMR studies (Fig. S16 , Table S9 ). The cytotoxicity of the native peptide [G10a]SHa and [G10a]SHa-BCTP conjugate was checked against MCF-7 cells at different doses (Fig. 2) . In contrast to the native peptide [G10a]SHa, the conjugate [G10a]SHa-BCTP was active against the MCF-7 breast cancer cell line without cytotoxicity against non-cancerous cells as indicated by MTT assay results for mouse fibroblast cell line (Table 3) . By using the reported cellgrowth on-bead assay [33] , we established that this peptide showed strong binding to MCF-7 cells (Fig. S17) . Further studies were carried out to understand the mechanism for the increased specificity of [G10a] SHa-BCTP for MCF-7 cells.
DNA fragmentation assay
Nature of cell death induced by peptides ([G10a]SHa and [G10a] SHa-BCTP conjugate was analyzed by DNA fragmentation using standard TUNEL assay to differentiate between apoptosis and necrosis (Fig. 3) . Cultured MCF-7 cells were treated with 0, 25, 50, and 100 μM of [G10a]SHa and [G10a]SHa-BCTP conjugate for 48 h. The [G10a]SHa treated cells demonstrated extremely low level of DNA fragmentation, as indicated by low fluorescein labeling at all doses (Fig. 3C, E and G) . However, intense fluorescence signals were observed for [G10a]SHa-BCTP conjugate at 25, 50 and 100 μM, thus indicating highly fragmented DNA (Fig. 3D, F and H ) and the dot plot pattern was similar to that of the positive control cells (Fig. 3A) .
From these observations, it can be concluded that [G10a]SHa peptide induced cell death via necrosis, whereas the [G10a]SHa-BCTP conjugate triggered apoptotic cell death in a dose-dependent manner. It is proposed that BCTP ligand facilitated receptor mediated delivery of [G10a]SHa-BCTP conjugate to breast cancer cells. The switching from necrosis to apoptosis may be due to the internalization of [G10a]SHa- Cells were then fixed, incubated with Bax primary/secondary antibodies and images were taken using fluorescence microscope (Nikon 90i microscope). Image J software was used to quantify the intensity of fluorescence light produced by images (Fig. E) .
BCTP conjugate, resulting in the delivery of peptide [G10a]SHa inside the cell to ultimately cause the induction of apoptosis.
Expression of pro-and anti-apoptotic genes following treatment with [G10a]SHa-BCTP conjugate
The results obtained from TUNEL assay indicated the apoptotic type of cell death by [G10a]SHa-BCTP conjugate and further molecular studies were performed with this peptide. Modulation in pro-and antiapoptotic gene expression (including Bax, Bcl-2, caspase-3 and survivin) was evaluated using real time PCR after treatment with [G10a] SHa-BCTP conjugate for 24 h. GAPDH gene expression was checked as a reference gene to normalize the data for each cDNA sample. Immunocytochemistry was performed to confirm the results at translational level.
Regulation of apoptosis is achieved by several types of proteins in a well programmed manner. Among these regulatory proteins, Bcl-2 family plays its critical role. This family includes various pro-and antiapoptotic factors, working in a strong co-ordination in response to intra-and extracellular environmental factors. Various peptides have been studied for their impact on Bcl-2 expression in human cancer cells. Bufalin, a peptide, has shown inhibition of ovarian tumor cells growth by down regulating Bcl-2 gene expression and Bax up-regulation [34] . In another report, a bioactive peptide, Chan Su, isolated from amphibian skin increased the expression of Bax protein and decreased Bcl-2 expression, thus resulting in apoptotic cell death [35] . In this study, the expression of Bcl-2 mRNA has been decreased significantly by [G10a] SHa-BCTP conjugate in MCF-7 cells (Fig. 4) .This decrease in Bcl-2 expression was dose-dependent that is 0.7 and 0.6 folds at 50 and 100 μM doses, respectively. Immunocytochemistry images showed similar pattern for Bcl-2 protein expression as that was obtained at mRNA level (Fig. 5) . Bcl-2 protein maintains the mitochondrial membrane integrity, prevent the release of cytochrome c in cytoplasm that ultimately inhibit the apoptosis to occur [36, 37] . Bcl-2 protein also blocks the activity of Bak and Bax proteins (both are apoptotic) by preventing their oligomerization. Bcl-2 can inhibit both type of apoptotic pathways either apoptosome dependent or independent [38] .
Few anticancer peptides have been reported for their effect on Bax protein expression [39, 40] . Results obtained from gene expression analysis of Bax with [G10a]SHa-BCTP conjugate treatment showed the significant decrease in Bax gene expression that was down to 0.88, 0.75 and 0.74 folds of untreated control cells at 25, 50 and 100 μM doses, respectively (Fig. 6 ). Since we have observed significant increase in Bax gene expression after [G10a]SHa-BCTP conjugate treatment, therefore, Bax / Bcl-2 ratio was calculated for all doses (Table 4) . These ratios become increased at 50 and 100 μM doses due to more decrease in Bcl-2 gene expression. However, fluorescence microscope images for Bax expression showed significant increase in Bax protein expression (Fig. 7) . Immunofluorescence images of MCF-7 cells for Bax protein indicate the increase at 25 and 50 μM dose after [G10a]SHa-BCTP conjugate treatment. However, at higher doses of 100 μM dose, Bax protein expression became limited to few spots due to 48 h treatment time. From these observations at mRNA and protein levels, it can be concluded that after [G10a]SHa-BCTP conjugate treatment, decrease in Bax gene expression might be overcome by more decrease in Bcl-2 gene expression resulting in the favorable conditions that induce apoptosis or it can be proposed that [G10a]SHa-BCTP conjugate regulates the Bax expression after transcription. Another proposed mechanism is the release of Bax protein from other protein complexes or cellular structures after [G10a]SHa-BCTP conjugate treatment. Bax is a monomeric protein and its expression induces apoptosis in cancer cells. It resides in cytosolic part normally while in apoptosis, it becomes attached with outer mitochondrial membrane and form pores in it that ultimately releases the several factors like cytochrome c and others.
Inhibitors of apoptosis (IAPs) are also involved in regulation of apoptosis. Survivin, an IAP, plays its role in cell division cycle in tumor cells [41] . Previous studies regarding survivin expression after peptides treatment showed that down regulation of survivin induce programmed cell death [42, 43] . In current study, [G10a]SHa-BCTP conjugate down regulated the survivin expression when compared with control cells. At 25 μM concentration, no change was observed (Fig. 8) . However, at 50 and 100 μM doses, survivin expression decreased significantly down to 0.7 folds of control cells. Similarly, survivin protein expression also decreased showing a good correlation with mRNA levels. Micrographs for survivin showed the change in its arrangement with decrease in its expression after treatment with [G10a]SHa-BCTP conjugate (Fig. 9) . In untreated control cells, survivin protein were located near the cell membrane. However, in 25 and 50 μM treated cells, expression of survivin decreased. Interestingly, at 100 μM dose, due to cell shrinkage survivin molecules aggregate together. This decrease in mRNA and protein expression clearly indicates that survivin down regulation is involved in programmed cell death at transcription as well as translation levels. Survivin exhibits its function through both extrinsic and intrinsic pathway of apoptosis (at the convergence point) and activates the caspase-3 and -7 [44] . RT-PCR was performed for survivin gene in triplicate for all doses and data was normalized using GAPDH. Cells incubated with complete medium only are represented by the bar labelled as Control. Data represents the mean of triplicates ± Standard deviation. One-way ANOVA was used for significant difference (i.e. * denotes p-value less 0.05, ** denotes p-value less 0.01 and *** denotes p-value less 0.001) when comparing treated samples with control cells. Cells were then fixed, incubated with survivin primary/secondary antibodies and images were taken using fluorescence microscope (Nikon 90i microscope). ImageJ software was used to quantify the intensity of fluorescence light produced by images (Fig. E) .
Caspases play their critical role in apoptosis, as they activate main catalytic enzymes required for programmed cell death. Caspase-3 is the most important among all caspases. Previous studies about the effect of AMPs using solid tumor cells showed caspase-3 activation resulting in apoptotic cell death [17, 45] . Similarly, in this study, [G10a]SHa-BCTP conjugate up-regulated the caspase-3 gene expression upto 4 to 5 folds in comparison with untreated control cells in MCF-7 cells (Fig. 10 ). This increase in caspase-3 expression is also supported by fluorescence micrographs for nuclear staining (DAPI) after treatment with [G10a]SHa-BCTP conjugate. These images indicate with increasing dose, decrease in cell number, nuclear condensation and formation of apoptotic bodies (Fig. 11) . Being an important constituent of cytoskeleton and one of the main substrate of caspases, β-actin protein pattern and arrangement was also checked. Images for treated cells deterioration of cytoskeleton structure at higher doses that was intact in control cells image (Fig. 12) . This destruction of β-actin protein structure, formation of apoptotic bodies and caspase-3 up-regulation validate the results obtained from TUNEL assay and confirms apoptosis induction. Caspase-3 plays its role as an executioner enzyme of caspase cascade (both extrinsic and intrinsic pathway) and further activates proteases and endonucleases. Endonucleases cut the nuclear material into short 180 bp fragments and proteases catalyze the actin structure, both helping in the formation of small apoptotic bodies.
Conclusions
By solid phase peptide synthesis, we prepared the frog antimicrobial peptide temporin-SHa and a series of analogs by replacing one or more glycine residues by D-alanine to improve peptide stability. Although the antimicrobial properties of temporin-SHa are well documented, we discovered that the natural peptide and analogs are inhibitors of human cancer cell lines in micromolar concentration. The highest activity was observed with [G10a]SHa and we conjugated this peptide with a breast cancer targeting peptide (BCTP) to improve selectivity. The temporin-BCTP conjugate was found to be a selective inhibitor of MCF-7 breast cancer cells. Further investigation of the mechanism revealed the conjugate induced apoptosis in MCF-7 cells through the up-regulation of caspase-3 expression and the inhibition of anti-apoptotic gene expression. Thus, conjugation to the breast cancer targeting peptide not only significantly improved the selectivity of [G10a]SHa but also switched the mechanism of cell death.
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